From epigenetics to epilepsy, via a channel in between. Ion channels, especially voltage-gated sodium channels, play indispensable roles in electrical signal generation in neurons, and the dysfunctions of ion channels are responsible for many devastating neurological diseases including epilepsy, chronic pain and autism. Sodium channel Nav1.6 is a major regulator of action potential threshold and neuronal excitability in both the peripheral and the central nervous system, and mutations of Nav1.6 have been found in increasing numbers of patients with epilepsy. This very interesting paper by Dr Huang and his team tackles the channelopathy-related epilepsy issue via the novel lens of epigenetics. Dr Huang’s team found that an epigenetic factor called chromodomain Y-like (CDYL) protein is negatively regulated by neuronal excitability. Using an elegant ChIP-seq approach, the authors demonstrated that SCN8A (the gene encoding Nav1.6 channel) is a target of CDYL and is negatively regulated by CDYL. The authors further provided evidence suggesting that increased neuronal excitability lowers CDYL expression, which in turn upregulates Nav1.6, leading to increased seizure susceptibility. As one hallmark of seizure is hyperexcitability of neurons, this whole pathway seems like a vicious circle that could heighten epilepsy in an auto-pilot model. Shockingly, the authors also found that human brain tissues from patients with epilepsy have decreased expression of CDYL and increased expression level of SCN8A. This finding is potentially groundbreaking as it points to a completely new way of how we view human epilepsy. Further down the road, there are many important questions to be addressed in future studies. For example, is there a causal link between epilepsy and the reduction of CDYL expression in human brain tissue? Would manipulation of CDYL be a potential therapeutic intervention for epilepsy? It has recently been reported that Nav1.6 knockout in cortical excitatory neurons reduces seizures, whereas in the thalamic reticular nucleus it leads to absence seizures {1}. Is it possible that targeting CDYL (instead of targeting Nav1.6 directly) may bypass the thalamus side effects? Regardless of these open questions, this paper represents one of the landmarks in the field that is worth recommending.